Biogen Inc
BIIB
Market Cap$31.09B
Close$
$286.24
30.3% upside
Current Fair Value
30.3% upsideUndervalued by 30.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $31.09 Billion |
|---|---|
| Enterprise Value | $36.55 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $8.0 |
| Beta | 0.0 |
| Outstanding Shares | 145,596,895 |
| Avg 30 Day Volume | 1,308,228 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 26.65 |
|---|---|
| PEG | 1879.34 |
| Price to Sales | 3.33 |
| Price to Book Ratio | 2.11 |
| Enterprise Value to Revenue | 3.78 |
| Enterprise Value to EBIT | 19.4 |
| Enterprise Value to Net Income | 31 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 0.43 |
Revenue Sources
No data
ESG Score
No data
About Biogen Inc
7,300 employees
CEO: Josephine Price At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therape...